Cargando…
Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States
Recent evidence suggests that some new SARS-CoV-2 variants with spike mutations, such as P.1 (Gamma) and B.1.617.2 (Delta), exhibit partial immune evasion to antibodies generated by natural infection or vaccination. By considering the Gamma and Delta variants in a multi-variant transmission dynamic...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132270/ https://www.ncbi.nlm.nih.gov/pubmed/34013295 http://dx.doi.org/10.1101/2021.05.10.21256996 |
_version_ | 1783694883454713856 |
---|---|
author | Sah, Pratha Vilches, Thomas N. Shoukat, Affan Fitzpatrick, Meagan C. Pandey, Abhishek Singer, Burton H. Moghadas, Seyed M. Galvani, Alison P. |
author_facet | Sah, Pratha Vilches, Thomas N. Shoukat, Affan Fitzpatrick, Meagan C. Pandey, Abhishek Singer, Burton H. Moghadas, Seyed M. Galvani, Alison P. |
author_sort | Sah, Pratha |
collection | PubMed |
description | Recent evidence suggests that some new SARS-CoV-2 variants with spike mutations, such as P.1 (Gamma) and B.1.617.2 (Delta), exhibit partial immune evasion to antibodies generated by natural infection or vaccination. By considering the Gamma and Delta variants in a multi-variant transmission dynamic model, we evaluated the dominance of these variants in the United States (US) despite mounting vaccination coverage and other circulating variants. Our results suggest that while the dominance of the Gamma variant is improbable, the Delta variant would become the most prevalent variant in the US, driving a surge in infections and hospitalizations. Our study highlights the urgency for accelerated vaccination and continued adherence to non-pharmaceutical measures until viral circulation is driven low. |
format | Online Article Text |
id | pubmed-8132270 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-81322702021-05-20 Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States Sah, Pratha Vilches, Thomas N. Shoukat, Affan Fitzpatrick, Meagan C. Pandey, Abhishek Singer, Burton H. Moghadas, Seyed M. Galvani, Alison P. medRxiv Article Recent evidence suggests that some new SARS-CoV-2 variants with spike mutations, such as P.1 (Gamma) and B.1.617.2 (Delta), exhibit partial immune evasion to antibodies generated by natural infection or vaccination. By considering the Gamma and Delta variants in a multi-variant transmission dynamic model, we evaluated the dominance of these variants in the United States (US) despite mounting vaccination coverage and other circulating variants. Our results suggest that while the dominance of the Gamma variant is improbable, the Delta variant would become the most prevalent variant in the US, driving a surge in infections and hospitalizations. Our study highlights the urgency for accelerated vaccination and continued adherence to non-pharmaceutical measures until viral circulation is driven low. Cold Spring Harbor Laboratory 2021-08-18 /pmc/articles/PMC8132270/ /pubmed/34013295 http://dx.doi.org/10.1101/2021.05.10.21256996 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator. |
spellingShingle | Article Sah, Pratha Vilches, Thomas N. Shoukat, Affan Fitzpatrick, Meagan C. Pandey, Abhishek Singer, Burton H. Moghadas, Seyed M. Galvani, Alison P. Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States |
title | Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States |
title_full | Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States |
title_fullStr | Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States |
title_full_unstemmed | Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States |
title_short | Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States |
title_sort | quantifying the potential dominance of immune-evading sars-cov-2 variants in the united states |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132270/ https://www.ncbi.nlm.nih.gov/pubmed/34013295 http://dx.doi.org/10.1101/2021.05.10.21256996 |
work_keys_str_mv | AT sahpratha quantifyingthepotentialdominanceofimmuneevadingsarscov2variantsintheunitedstates AT vilchesthomasn quantifyingthepotentialdominanceofimmuneevadingsarscov2variantsintheunitedstates AT shoukataffan quantifyingthepotentialdominanceofimmuneevadingsarscov2variantsintheunitedstates AT fitzpatrickmeaganc quantifyingthepotentialdominanceofimmuneevadingsarscov2variantsintheunitedstates AT pandeyabhishek quantifyingthepotentialdominanceofimmuneevadingsarscov2variantsintheunitedstates AT singerburtonh quantifyingthepotentialdominanceofimmuneevadingsarscov2variantsintheunitedstates AT moghadasseyedm quantifyingthepotentialdominanceofimmuneevadingsarscov2variantsintheunitedstates AT galvanialisonp quantifyingthepotentialdominanceofimmuneevadingsarscov2variantsintheunitedstates |